{"id":671070,"date":"2026-05-14T20:01:11","date_gmt":"2026-05-14T20:01:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/671070\/"},"modified":"2026-05-14T20:01:11","modified_gmt":"2026-05-14T20:01:11","slug":"funding-of-weight-loss-drug-wegovy-expected-to-come-swiftly","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/671070\/","title":{"rendered":"Funding of weight-loss drug Wegovy expected to come swiftly"},"content":{"rendered":"<p><img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2025\/11\/4K4YKR9_AFP__20240712__dpa_pa_240712_99_710132_dpai__v1__HighRes__SlimmingSyringes_jpg\" width=\"1050\" height=\"769\" alt=\"Wegovy slimming medication at a pharmacy in Berlin.\"\/><\/p>\n<p class=\"photo-captioned__information\">\nPharmac has added Wegovy to its list of medicines suitable for future funding.<br \/>\nPhoto: Jens Kalaene \/ AFP\n<\/p>\n<p>A paediatrican who treats obese teens expects funding to come swiftly for weight loss drug Wegovy.<\/p>\n<p>Pharmac has added the drug to its list of medicines suitable for future funding.<\/p>\n<p>In a decision released on Thursday, the drug-funding agency confirmed it <a href=\"https:\/\/www.rnz.co.nz\/news\/health\/595245\/pharmac-adds-wegovy-for-weight-loss-to-list-for-future-funding\" rel=\"nofollow noopener\" target=\"_blank\">had added Semaglutide &#8211; brand name Wegovy &#8211; to its list<\/a> of &#8216;Options For Investment&#8217;, which includes all the medications that Pharmac would fund, if the budget allowed.<\/p>\n<p>Currently unfunded, Wegovy would cost someone about $400 a month.<\/p>\n<p>The order of Pharmac&#8217;s list is not made public for commercial reasons, but if chosen, the drug would be available to people with a Body Mass Index (BMI) of more than 50 and also to those with a BMI of more than 35 with at least two co-morbidities.<\/p>\n<p>Auckland University paediatric endocrinology professor Wayne Cutfield said questions remained over final eligibility criteria, whether the drug would be fully funded or subsidised, and &#8211; crucially &#8211; when, but he did not expect to wait long.<\/p>\n<p><img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/05\/4MFO2P2_copyright_image_254681.jpeg\" width=\"576\" height=\"691\" alt=\"No caption\"\/><\/p>\n<p class=\"photo-captioned__information\">\nAuckland University paediatric endocrinology professor Wayne Cutfield.<br \/>\nPhoto: Liggins Institute\n<\/p>\n<p>&#8220;This isn&#8217;t the only drug in their cross-hairs that they [Pharmac] are considering,&#8221; he said. &#8220;Yes, it&#8217;s big and, yes, it&#8217;s important, but I don&#8217;t know if it will be weeks or months.<\/p>\n<p>&#8220;I have no idea, but it&#8217;s not going to be years.&#8221;<\/p>\n<p>Cutfield said the cost of the drug was prohibitive for many and, if approved as recommended, a huge number of New Zealanders &#8211; including teens &#8211; would benefit.<\/p>\n<p>&#8220;They use the term &#8216;people&#8217;, which doesn&#8217;t exclude teenagers, because Wegovy in New Zealand [is] licensed for those over the age of 12. In Australia, it is a far more exclusive recommendation that has been imposed.&#8221;<\/p>\n<p>Weight loss specialist Gerard McQuinlan said the addition of Wegovy to Pharmac&#8217;s list was significant and the recommended eligibility criteria made sense.<\/p>\n<p>He said comorbidities, such as high blood pressure, obstructive sleep apnea and diabetes, were all improved by weight loss and funded Wegovy could potentially deliver savings to the healthcare system.<\/p>\n<p>McQuinlan hoped approval would come before 2030 and expected Wegovy to be fully funded, with people paying no more than the standard $5 prescription fee.<\/p>\n<p><a href=\"https:\/\/radionz.us6.list-manage.com\/subscribe?u=211a938dcf3e634ba2427dde9&amp;id=b3d362e693\" rel=\"nofollow noopener\" target=\"_blank\">Sign up for Ng\u0101 Pitopito K\u014drero<\/a>, a daily newsletter curated by our editors and delivered straight to your inbox every weekday.<\/p>\n","protected":false},"excerpt":{"rendered":"Pharmac has added Wegovy to its list of medicines suitable for future funding. Photo: Jens Kalaene \/ AFP&hellip;\n","protected":false},"author":2,"featured_media":454277,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[64,1590,63,1589,137,490,44,1591,1588,1586,1587],"class_list":["post-671070","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-au","tag-audio","tag-australia","tag-current-affairs","tag-health","tag-medication","tag-news","tag-podcasts","tag-public-radio","tag-radio-new-zealand","tag-rnz"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/671070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=671070"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/671070\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/454277"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=671070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=671070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=671070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}